

Financial news for GEVA dated on 2016-09-21: 22 Stocks With Three-Day Increasing Volume

Financial news for GEVA dated on 2015-07-27: Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk

Financial news for GEVA dated on 2015-07-09: JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue

Financial news for GEVA dated on 2015-06-26: EU Medicines Agency Recommends Approval Of Enzyme Replacement Therapy For Paediatric-Onset Hypophosphatasia From Alexion Pharma

Financial news for GEVA dated on 2015-06-23: Bernstein: Alexion Pharma An Outperform, Worth \$267/Share

Financial news for GEVA dated on 2015-06-22: Alexion Accepts Shares of Synageva BioPharma Tendered Into Exchange Offer

Financial news for GEVA dated on 2015-06-04: Synageva Reports Closing of Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB

Financial news for GEVA dated on 2015-05-29: Alexion, Synageva Says FTC Terminates Early Waiting Period For Alexion's Acquisition Of Synageva Under Hart-Scott-Rodino Antitrust Improvement Act

Financial news for GEVA dated on 2015-05-26: Synageva BioPharma Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan

Financial news for GEVA dated on 2015-05-11: Oppenheimer Downgrades Dyax

Financial news for GEVA dated on 2015-05-07: Morgan Stanley: Market's Reaction To Linger For Alexion Pharmaceuticals

Financial news for GEVA dated on 2015-05-07: Here's What Canaccord Learned After Spending A Day With Synageva's Management

Financial news for GEVA dated on 2015-05-07: Benzinga's Volume Movers

Financial news for GEVA dated on 2015-05-07: Benzinga's Top Downgrades

Financial news for GEVA dated on 2015-05-07: How Wedbush Sees The Alexion-Synageva Deal

Financial news for GEVA dated on 2015-05-07: Baird Downgrades Synageva BioPharma to Neutral

Financial news for GEVA dated on 2015-05-06: Benzinga's M&A Chatter for Wednesday May 6, 2015

Financial news for GEVA dated on 2015-05-06: Benzinga's Volume Movers

Financial news for GEVA dated on 2015-05-06: Synageva Shares Soar 116% On Buyout Deal With Alexion Pharmaceuticals

Financial news for GEVA dated on 2015-05-06: Stocks Hitting 52-Week Highs

Financial news for GEVA dated on 2015-05-06: Morning Market Losers

Financial news for GEVA dated on 2015-05-06: Morning Market Gainers

Financial news for GEVA dated on 2015-05-06: Synageva BioPharma Shares Rise 129% Premarket Following Announcement of Deal to be Acquired by Alexion

Financial news for GEVA dated on 2015-05-06: Benzinga's Top #PreMarket Losers

Financial news for GEVA dated on 2015-05-06: Benzinga's Top #PreMarket Gainers

Financial news for GEVA dated on 2015-05-06: UPDATE: Alexion to Acquire Synageva for \$115/Share in Cash, 0.6581 Shares of Alexion Stock

Financial news for GEVA dated on 2015-05-06: Alexion To Acquire Synageva for \$8.4B

Financial news for GEVA dated on 2015-04-29: Synageva BioPharma Reports Q1 EPS -\$1.63 Vs Est -\$1.70, Sales \$927K Vs Est \$1.19M

Financial news for GEVA dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for GEVA dated on 2015-03-30: US Stock Futures Surge Ahead Of Economic Data

Financial news for GEVA dated on 2015-03-30: Synageva BioPharma Submits Kanuma Application for LAL Deficiency In Mexico

Financial news for GEVA dated on 2015-03-02: JP Morgan Downgrades Synageva BioPharma to Neutral

Financial news for GEVA dated on 2015-02-27: Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma

Financial news for GEVA dated on 2015-01-26: Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted

Financial news for GEVA dated on 2015-01-12: Clear Channel Outdoor, Oasis Petroleum And Other Insiders Have Been Buying

Financial news for GEVA dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for GEVA dated on 2015-01-07: 4 More Biotech Secondaries Investors Are Watching

Financial news for GEVA dated on 2015-01-07: Benzinga's Volume Movers

Financial news for GEVA dated on 2015-01-06: Synageva BioPharma Prices 3M Share Offering at \$94.19/Share

Financial news for GEVA dated on 2015-01-06: 4 Biotech Secondary Offerings Traders Are Watching

Financial news for GEVA dated on 2015-01-05: Synageva BioPharma Announces A 2.5M Share Common Stock Offering

Financial news for GEVA dated on 2015-01-05: Synageva BioPharma Announces New Pipeline Programs And Other Company Progress

Financial news for GEVA dated on 2014-12-23: Synageva BioPharma Announces Validation of The MAA For Sebelipase Alfa For LAL Deficiency.

Financial news for GEVA dated on 2014-12-15: Synageva BioPharma Announces Active Investigational NDA for SBC-103 for Treatment Of Mucopolysaccharidosis IIIB

Financial news for GEVA dated on 2014-12-02: Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa

Financial news for GEVA dated on 2014-10-23: Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting

Financial news for GEVA dated on 2014-10-08: Synageva Says Sebelipase Alfa Phase 3 Data Selected for Oral Presentation During Late-Breaking Session At The Liver Meeting(r)

Financial news for GEVA dated on 2014-09-22: Synageva BioPharma Names Robert Bazemore as COO

Financial news for GEVA dated on 2014-07-02: Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

Financial news for GEVA dated on 2014-07-01: Dow Flirts With 17,000, S&P 500 Inches Closer To 2,000 In First Trading Day Of The Third Quarter

Financial news for GEVA dated on 2014-07-01: Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

Financial news for GEVA dated on 2014-07-01: Mid-Day Market Update: Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

Financial news for GEVA dated on 2014-07-01: Markets Surge; GM June Sales Rise 1%

Financial news for GEVA dated on 2014-07-01: Morning Market Losers

Financial news for GEVA dated on 2014-07-01: Citigroup Initiates Coverage on Synageva BioPharma Corp. at Neutral, Announces \$113.00 PT

Financial news for GEVA dated on 2014-06-30: Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related

## Abnormalities

Financial news for GEVA dated on 2014-04-30: Synageva BioPharma Corp. Reports Q1 EPS of \$(1.16); Revenue of \$1.59M

Financial news for GEVA dated on 2014-04-08: Wedbush Upgrades Synageva BioPharma Corp. to Outperform, Maintains \$93.00 PT

Financial news for GEVA dated on 2014-04-01: UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step

Financial news for GEVA dated on 2014-03-05: Synageva Biopharma Prices 2M Shares at \$105.75/Share

Financial news for GEVA dated on 2014-03-04: UPDATE: Synageva Biopharma(tm) Announces 2M Share Proposed Public Offering of Its Common Stock

Financial news for GEVA dated on 2014-03-04: Synageva Announces 2M Share Proposed Offering of Common Shares

Financial news for GEVA dated on 2014-03-04: Synageva Awarded US Patent for Treatment of LAL Deficiency

Financial news for GEVA dated on 2014-03-03: Synageva BioPharma Qtr. Loss of \$1/Share; Sees FY14 Loss \$190-205M Range

Financial news for GEVA dated on 2014-02-18: Intercept Names Sanj K. Patel and Glenn Sblendorio to Board of Directors

Financial news for GEVA dated on 2014-02-10: JP Morgan Upgrades Synageva BioPharma Corp. to Outperform, Raises PT to \$110.00

Financial news for GEVA dated on 2014-01-08: Nomura Initiates Coverage on Synageva BioPharma Corp. at Buy, Announces \$85.00 PT

Financial news for GEVA dated on 2014-01-07: Baird Initiates Coverage on Synageva BioPharma Corp. at Outperform, Announces \$83.00 PT

Financial news for GEVA dated on 2014-01-06: Synageva Issues Update on Clinical Trial with Sebelipase ALFA, Says Trial Enrollment Exceeded Target of 50 Patients

Financial news for GEVA dated on 2013-12-02: Synageva BioPharma Completes Target Enrollment in Phase 3 ARISE Trial

Financial news for GEVA dated on 2013-11-15: Benzinga's Top Initiations

Financial news for GEVA dated on 2013-11-15: UPDATE: Goldman Sachs initiates on Synageva Following Positive Phase II Data On Sebelipase

Financial news for GEVA dated on 2013-11-15: Goldman Sachs Initiates Coverage on Synageva BioPharma Corp. at Buy, Announces \$72.00 PT

Financial news for GEVA dated on 2013-10-29: Synageva BioPharma Corp. Reports Q3 EPS of \$(1.02) vs \$(0.89) Est

Financial news for GEVA dated on 2013-10-22: UPDATE: Leerink Swann Downgrades Synageva BioPharma Corp. on Lack of NT News Flow, Market Opportunity Visibility

Financial news for GEVA dated on 2013-10-21: Leerink Swann Downgrades Synageva BioPharma Corp. to Market Perform

Financial news for GEVA dated on 2013-10-07: UPDATE: Wedbush Downgrades Synageva BioPharma on Valuation

Financial news for GEVA dated on 2013-10-07: Wedbush Downgrades Synageva BioPharma Corp. to Neutral, Raises PT to \$67.00

Financial news for GEVA dated on 2013-10-07: Wedbush Downgrades Synageva BioPharma Corp. to Neutral

Financial news for GEVA dated on 2013-09-30: Synageva Biopharma Closes Offering of 3.16M Share Offering at \$56.63/Share for Proceeds of \$179M

Financial news for GEVA dated on 2013-09-25: Benzinga's Volume Movers

Financial news for GEVA dated on 2013-09-24: Synageva BioPharma Prices 2.75M Share Offering at \$56.63/Share

Financial news for GEVA dated on 2013-09-23: Synageva Biopharma Announces 2.75M Share

## Offering of Common Stock

Financial news for GEVA dated on 2013-08-05: Synageva BioPharma Corp. Reports Q2 EPS of \$(0.81) vs \$(0.78) Est

Financial news for GEVA dated on 2013-05-20: Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration

Financial news for GEVA dated on 2013-05-20: Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation from FDA

Financial news for GEVA dated on 2013-05-10: Market Wrap for Friday, May 10: Stocks Gain on Late Day Rally

Financial news for GEVA dated on 2013-05-10: UPDATE: J.P. Morgan Downgrades Synageva BioPharma to Neutral on Challenges Ahead

Financial news for GEVA dated on 2013-05-10: A Peek Into The Market Before The Trading Starts

Financial news for GEVA dated on 2013-05-10: Benzinga's Top Downgrades

Financial news for GEVA dated on 2013-05-10: JP Morgan Downgrades Synageva BioPharma Corp. to Neutral, Lowers PT to \$50.00

Financial news for GEVA dated on 2013-05-07: Synageva BioPharma Corp. Reports Q1 EPS of \$(0.54) vs \$(0.70) Est

Financial news for GEVA dated on 2013-04-08: Form 8-K Shows Synageva Biopharma Entered Deal with Shire Human Genetics, Synageva to Pay \$2.5M Upfront, Two Sales-Based Milestones; In Settlement Pact with Children's Hospital Meial Center

Financial news for GEVA dated on 2013-03-12: UPDATE: Wedbush Raises PT to \$55 on Synageva BioPharma on Valuation, First Patient ARISE Dose

Financial news for GEVA dated on 2013-03-12: UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment

Financial news for GEVA dated on 2013-03-12: Piper Jaffray Maintains Neutral on Synageva BioPharma Corp., Raises PT to \$57.00

Financial news for GEVA dated on 2013-03-12: Wedbush Maintains Outperform on Synageva BioPharma Corp., Raises PT to \$55.00

Financial news for GEVA dated on 2013-03-11: Synageva BioPharma Corp. Reports Q4 EPS of \$(0.62) vs \$(0.60) Est; Revenue of \$4.90M vs \$2.32M Est

Financial news for GEVA dated on 2013-01-22: Synageva Biopharma Entered Bioprocessing Services Deal with Diosynth

Financial news for GEVA dated on 2013-01-09: Top Insider Trades: Purchases at Synageva BioPharma and Lucas Energy

Financial news for GEVA dated on 2013-01-09: Synageva Biopharma Closes Offering of 2.47M Shares at \$47.53/Share

Financial news for GEVA dated on 2013-01-04: UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Synageva BioPharma Corp.

Financial news for GEVA dated on 2013-01-04: Piper Jaffray Maintains Neutral on Synageva BioPharma Corp., Lowers PT to \$53.00

Financial news for GEVA dated on 2013-01-03: Synageva Prices 2.15M Share Public Offering at \$47.53/Share

Financial news for GEVA dated on 2013-01-03: UPDATE: Piper Jaffray Downgrades Synageva to Neutral on Lack of Near-Term Catalysts

Financial news for GEVA dated on 2013-01-03: Synageva Announces \$80M Proposed Offering of Common Stock

Financial news for GEVA dated on 2013-01-03: Piper Jaffray Downgrades Synageva BioPharma Corp. to Neutral, Lowers PT to \$57.00

Financial news for GEVA dated on 2013-01-02: Janney Capital Initiates Coverage on Synageva BioPharma Corp. at Neutral, Announces \$52.00 PT

Financial news for GEVA dated on 2012-11-07: UPDATE: Wedbush Securities Reiterates

Outperform Rating, Raises PT on Synageva BioPharma Corp.

Financial news for GEVA dated on 2012-11-06: Wedbush Securities Maintains Synageva Biopharma at Outperform, Raises PT from \$42 to \$50

Financial news for GEVA dated on 2012-10-03: Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

Financial news for GEVA dated on 2012-09-06: Benzinga's Top Initiations

Financial news for GEVA dated on 2012-09-06: UPDATE: Piper Jaffray Initiates Synageva at Overweight with \$66 PT on Lead Drug Data

Financial news for GEVA dated on 2012-09-06: Piper Jaffray Initiates Coverage on Synageva Biopharma at Overweight, Announces PT of \$66

Financial news for GEVA dated on 2012-09-05: Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

Financial news for GEVA dated on 2012-07-10: Synageva Biopharma Announces Pricing of 2.43M Share Offering at \$41.20

Financial news for GEVA dated on 2012-07-09: Synageva BioPharma Announces \$80 Million Proposed Public Offering of Common Stock

Financial news for GEVA dated on 2012-06-29: Four Winning Trades Based on Analyst Calls

Financial news for GEVA dated on 2012-06-29: ThinkEquity Initiates Coverage On Synageva Biopharma at Buy

Financial news for GEVA dated on 2012-06-25: Winning Trades Based on Analyst Ratings for June 25

Financial news for GEVA dated on 2012-06-25: Synageva BioPharma Jumps on Canaccord Genuity Initiation

Financial news for GEVA dated on 2012-06-25: UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, \$60 PT; Attractive Orphan Platform

Financial news for GEVA dated on 2012-06-25: Canaccord Initiates Coverage On Synageva Biopharma at Buy, Announces PT of \$60

Financial news for GEVA dated on 2012-05-23: Synageva Biopharma Files \$150M Mixed Securities Shelf

Financial news for GEVA dated on 2012-04-23: Synageva BioPharma Falls 3%

Financial news for GEVA dated on 2012-04-20: UPDATE: Morgan Stanley Initiates Synageva Biopharma with Buy, \$76 PT

Financial news for GEVA dated on 2012-04-02: Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program

Financial news for GEVA dated on 2012-04-02: Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program

Financial news for GEVA dated on 2012-02-09: Synageva BioPharma Announces Interim Data at 8th Annual Lysosomal Disease Network World Symposium

Financial news for GEVA dated on 2012-01-05: Synageva BioPharma Announces Pricing of Public Offering of Common Stock at \$25.18 per Share

Financial news for GEVA dated on 2012-01-04: Synageva BioPharma Announces \$60 Million Proposed Public Offering of Common Stock

Financial news for GEVA dated on 2011-12-22: Synageva BioPharma Completes Enrollment in Phase I/II Clinical Trial of SBC-102 for Late Onset LAL Deficiency and Announces Other Company Progress

Financial news for GEVA dated on 2011-12-14: End-of-Day Market Summary for December 14, 2011

Financial news for GEVA dated on 2011-12-14: Afternoon Movers; Euro Contagion Spurs Fear

Financial news for GEVA dated on 2011-12-09: Investor Ideas' Thursday's Biotech Stocks to Watch

Financial news for GEVA dated on 2011-12-09: Investor Ideas' Thursday's Biotech  
Stocks to Watch